NASDAQ:MOR - MorphoSys Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$22.65
▼ -0.53 (-2.29%)
1 month | 3 months | 12 months
Get New MorphoSys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for MorphoSys in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $22.65.
Hold
The current consensus among 10 contributing investment analysts is to hold stock in MorphoSys. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
3/29/2021Morgan StanleyReiterated RatingEqual WeightLow
i
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformN/A
i
Rating by G. Porges at SVB Leerink LLC
3/23/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformLow
i
Rating by G. Porges at SVB Leerink LLC
12/21/2020Berenberg BankReiterated RatingBuyLow
i
12/7/2020Smith Barney CitigroupReiterated RatingBuyHigh
i
11/25/2020Morgan StanleyInitiated CoverageEqual WeightMedium
i
11/18/2020The Goldman Sachs GroupInitiated CoverageNeutralMedium
i
11/13/2020BarclaysReiterated RatingEqual WeightN/A
i
10/2/2020BarclaysReiterated RatingEqual WeightN/A
i
8/10/2020CitigroupInitiated CoverageBuyN/A
i
6/25/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformN/A
i
5/13/2020BarclaysReiterated RatingEqual WeightN/A
i
5/12/2020HSBCUpgradeReduce ➝ HoldN/A
i
1/14/2020SVB LeerinkReiterated RatingOutperformHigh
i
Rating by G. Porges at SVB Leerink LLC
11/27/2019GuggenheimInitiated CoverageBuyN/A
i
11/19/2019GuggenheimInitiated CoverageBuyN/A
i
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuyN/A
i
4/2/2019Berenberg BankUpgradeHold ➝ BuyN/A
i
1/11/2019SVB LeerinkReiterated RatingOutperformLow
i
Rating by G. Porges at SVB Leerink LLC
12/10/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyN/A
i
11/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$32.00 ➝ $34.00N/A
i
11/5/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$38.00N/A
i
9/7/2018Berenberg BankDowngradeBuy ➝ HoldN/A
i
7/30/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldN/A
i
5/17/2018JPMorgan Chase & Co.Initiated CoverageOverweightN/A
i
5/14/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/A
i
(Data available from 4/18/2016 forward)
MorphoSys logo
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Today's Range

Now: $22.65
$22.50
$23.00

50 Day Range

MA: $23.37
$21.56
$25.64

52 Week Range

Now: $22.65
$21.27
$35.73

Volume

34,176 shs

Average Volume

61,917 shs

Market Capitalization

$2.98 billion

P/E Ratio

107.86

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of MorphoSys?

The following Wall Street sell-side analysts have issued reports on MorphoSys in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Morgan Stanley, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MOR.

What is the current price target for MorphoSys?

0 Wall Street analysts have set twelve-month price targets for MorphoSys in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MorphoSys in the next year.
View the latest price targets for MOR.

What is the current consensus analyst rating for MorphoSys?

MorphoSys currently has 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MOR, but not buy more shares or sell existing shares.
View the latest ratings for MOR.

What other companies compete with MorphoSys?

How do I contact MorphoSys' investor relations team?

MorphoSys' physical mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company's listed phone number is 49 89 89927 0 and its investor relations email address is [email protected] The official website for MorphoSys is www.morphosys.com.